2.64Open2.64Pre Close0 Volume3 Open Interest17.00Strike Price0.00Turnover84.84%IV2.71%PremiumMay 16, 2025Expiry Date2.24Intrinsic Value100Multiplier15DDays to Expiry0.40Extrinsic Value100Contract SizeAmericanOptions Type-0.7614Delta0.1207Gamma5.79Leverage Ratio-0.0245Theta-0.0049Rho-4.41Eff Leverage0.0095Vega
uniQure NV Stock Discussion
Revolutionary Gene Therapy for Huntington's Disease Earns FDA Breakthrough Status After Promising Trial Results
uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease
Benzinga· 23 mins ago
Revolutionary Hemophilia B Treatment Eliminates Need for Regular Therapy in 94% of Patients
share your thoughts & ideas explain why 2025 will be amazing several break free and run
apextradez Wins so can you
No comment yet